Pamrevlumab Emerging Drug Insight

“Pamrevlumab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about pamrevlumab for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets. A detailed picture of the pamrevlumab in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the pamrevlumab. The Pamrevlumab Market Size Report provides insights into the Pamrevlumab mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones and other developmental activities. Further, it also consists of future market assessments inclusive of the pamrevlumab market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Pamrevlumab Drug Summary

FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. After successfully completing the Phase II Pamrevlumab Clinical Trials study, FibroGen is advancing pamrevlumab in Phase III clinical development for the Idiopathic Pulmonary Fibrosis treatment.

The company is conducting two randomized, double-blind, placebo-controlled Phase III studies of pamrevlumab in IPF. Each study has a primary efficacy endpoint (for the US) of change from baseline in forced vital capacity (FVC). For Europe, these trials have a primary efficacy endpoint of disease progression (defined by a decline in FVC percent predicted of greater than or equal to 10% or death). Secondary endpoints will include clinical outcomes of disease progression, acute IPF exacerbations, patient reported outcomes, and quantitative changes in lung fibrosis volume from baseline. Enrollment in the ZEPHYRUS-1 trial (the first Phase III trial of pamrevlumab in 356 IPF patients) is completed. While the company continues to enroll patients in ZEPHYRUS-2, the second Phase III trial of pamrevlumab in approximately 340 Idiopathic Pulmonary Fibrosis Patients.

Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the Duchenne muscular dystrophy Treatment, and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients. As per the latest reports by FibroGen, topline data from the ZEPHYRUS-1 Phase III study of pamrevlumab in IPF is expected in mid-2023.

Pamrevlumab Market Forecast Report Scope

The Pamrevlumab Market Forecast Report provides insights into:

• A comprehensive product overview including the pamrevlumab description, Pamrevlumab Mechanism of Action, dosage and administration, research and development activities in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF).
• Elaborated details on pamrevlumab regulatory milestones and other development activities have been provided in this report.
• The Pamrevlumab Market Size Report also highlights the pamrevlumab research and development activities in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) across the United States, Europe, and Japan.
• The Pamrevlumab Market Size Report also covers the patent information and the expiration timeline for pamrevlumab.
• The Pamrevlumab Market Forecast Report contains forecasted sales for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) till 2032.
• Comprehensive coverage of the late-stage Pancreatic Cancer Emerging Therapies, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF).
• The Pamrevlumab Market Size Report also features the SWOT analysis with analyst views for pamrevlumab in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF).

Pamrevlumab Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

Pamrevlumab Market Analytical Perspective by DelveInsight

In-depth Pamrevlumab Market Assessment

This Pamrevlumab Market Forecast Report provides a detailed market assessment of pamrevlumab for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Pamrevlumab Clinical Trials Assessment

The Pamrevlumab Market Forecast Report provides the clinical trial information of pamrevlumab for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF), covering trial interventions, trial conditions, trial status, start and completion dates.

Pamrevlumab Market Forecast Report Highlights 

• In the coming years, the Pamrevlumab Market scenario for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The Pamrevlumab Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence pamrevlumab dominance.
• Other emerging products for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) are expected to give tough market competition to pamrevlumab and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of pamrevlumab in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF).
• Our in-depth analysis of the forecasted Pamrevlumab sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the pamrevlumab in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF).

Key Questions

• What is the product type, route of administration and Pamrevlumab mechanism of action?
• What is the Pamrevlumab clinical trial status of the study related to pamrevlumab in Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the pamrevlumab development?
• What are the key designations that have been granted to pamrevlumab for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF)?
• What is the Pamrevlumab Market Forecasted scenario for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF)?
• What are the forecasted Pamrevlumab sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available, and how are these giving competition to pamrevlumab for Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF)?
• Which are the late-stage emerging therapies under development for the treatment of Pancreatic Cancer, Progressive Fibrosing Interstitial Lung Diseases (PF-ILD), and Idiopathic Pulmonary Fibrosis (IPF)?

Stay Updated with us for Recent Articles @ Latest DelveInsight Blogs